More articles about Business, Policy & Funding

The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

The university is arguing that the judge had no basis to compel arbitration of what Cornell is claiming is a fraudulent settlement.

The $649 NGS test screens for 193 disorders, can be ordered online, and is designed to supplement standard state newborn screening services. 

During the quarter, the company reopened its CLIA lab in New Haven, Connecticut, following the company's merger with Transgenomic in June.

Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.

Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.

Revenue increases for the firm's for high-throughput genomics and mass cytometry products were offset by declines in single-cell genomics product sales.

DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.

The US ITC has ruled that Oxford Nanopore's products do not infringe on single-molecule sequencing-related patents held by PacBio. 

Clive Brown, the company's chief technology officer, provided an update on the firm's business and talked about new products and planned improvements.

 

The partnership will allow customers using NEBNext Direct target enrichment products to analyze data with the Bluebee platform.

The spending deal comes amid efforts by lawmakers to avoid another government shutdown, and includes lifting the national debt limit through March 1, 2019.

The Sentosa SA201 HSV-1/2 PCR test detects herpes virus DNA from oral or anal skin lesions in symptomatic patients.

Launch Diagnostics will distribute BioGx's entire product line, including laboratory-use-only products, in the UK and Ireland.

The biomarker has been associated with retinal ganglion cell death and is upregulated in mouse models of chronic glaucoma.

OnRamp will provide its systems and services for next-generation sequencing data analysis on the Science Exchange platform.

The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.

The molecular test can provide results in 30 minutes from nasal swabs on a palm-sized instrument.

The firm reported total revenues of $194 million, compared to $196.5 million in Q2 2017, but beat the consensus Wall Street estimate of $188.8 million.

Pages

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.